Cover Image
Market Research Report

Global Traumatic Brain Injury Therapeutics Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 759934
Published Content info 118 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Traumatic Brain Injury Therapeutics Market 2019-2023
Published: December 10, 2018 Content info: 118 Pages
Description

About this market:

TBI is also known as an intracranial injury. It occurs when an external force causes damage to the brain. The high prevalence of TBI globally is because of the increase in the number of falls road accidents, and other causes. In most of these cases people with TBI need to be hospitalized. The prevalence of TBI among various age groups and eternal causes are important driving factors for the global TBI therapeutics market. The traumatic brain injury therapeutics market growth at a CAGR of close to 5% during the forecast period

Market Overview:

Array of new drug approvals

The drug development process is a long and expansive process. The number of molecules under development for the treatment of TBI is increasing at a substantial rate because of the rising prevalence of TBI globally.

Preference for substitutes

Most drugs are mostly symptomatic and not curative. The substitutes prove to be more efficient and are preferred among patients. This is expected to pose a challenge to the market.

For the detailed list of factors that will drive and challenge the growth of the traumatic brain injury therapeutics market during the 2019-2023, view our report.

Competitive Landscape:

The global traumatic brain injury therapeutics market is extremely fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR30416

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Anticonvulsants - Market size and forecast 2018-2023
  • Anti-anxiety agents - Market size and forecast 2018-2023
  • Anticoagulants - Market size and forecast 2018-2023
  • Analgesics - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Baxter
  • Fresenius
  • Johnson & Johnson Services
  • Novartis
  • Pfizer

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global CNS therapeutics market
  • Exhibit 03: Segments of global CNS therapeutics market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Anticonvulsants - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Anticonvulsants - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Anti-anxiety agents - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Anti-anxiety agents - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Anticoagulants - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Anticoagulants - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Analgesics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Analgesics - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: Other therapeutics - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Market opportunity by product
  • Exhibit 31: Customer landscape
  • Exhibit 32: Market share by geography 2018-2023 (%)
  • Exhibit 33: Geographic comparison
  • Exhibit 34: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Americas
  • Exhibit 38: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in EMEA
  • Exhibit 41: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 42: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 43: Top 3 countries in APAC
  • Exhibit 44: Key leading countries
  • Exhibit 45: Market opportunity
  • Exhibit 46: Decision framework
  • Exhibit 01: TBI-related hospitalizations by age group and injury mechanism in US 2006-2010
  • Exhibit 02: Impact of drivers and challenges
  • Exhibit 03: Awareness initiatives of TBI
  • Exhibit 04: Vendor landscape
  • Exhibit 05: Landscape disruption
  • Exhibit 06: Vendors covered
  • Exhibit 07: Vendor classification
  • Exhibit 08: Market positioning of vendors
  • Exhibit 09: Baxter - Vendor overview
  • Exhibit 10: Baxter - Business segments
  • Exhibit 11: Baxter - Organizational developments
  • Exhibit 12: Baxter - Geographic focus
  • Exhibit 13: Baxter - Segment focus
  • Exhibit 14: Baxter - Key offerings
  • Exhibit 15: Baxter - Key customers
  • Exhibit 16: Fresenius - Vendor overview
  • Exhibit 17: Fresenius - Business segments
  • Exhibit 18: Fresenius - Organizational developments
  • Exhibit 19: Fresenius - Geographic focus
  • Exhibit 20: Fresenius - Segment focus
  • Exhibit 21: Fresenius - Key offerings
  • Exhibit 22: Fresenius - Key customers
  • Exhibit 23: Johnson & Johnson Services - Vendor overview
  • Exhibit 24: Johnson & Johnson Services - Business segments
  • Exhibit 25: Johnson & Johnson Services - Organizational developments
  • Exhibit 26: Johnson & Johnson Services - Geographic focus
  • Exhibit 27: Johnson & Johnson Services - Segment focus
  • Exhibit 28: Johnson & Johnson Services - Key offerings
  • Exhibit 29: Johnson & Johnson Services - Key customers
  • Exhibit 30: Novartis - Vendor overview
  • Exhibit 31: Novartis - Business segments
  • Exhibit 32: Novartis - Organizational developments
  • Exhibit 33: Novartis - Geographic focus
  • Exhibit 34: Novartis - Segment focus
  • Exhibit 35: Novartis - Key offerings
  • Exhibit 36: Novartis - Key customers
  • Exhibit 37: Pfizer - Vendor overview
  • Exhibit 38: Pfizer - Business segments
  • Exhibit 39: Pfizer - Organizational developments
  • Exhibit 40: Pfizer - Geographic focus
  • Exhibit 41: Pfizer - Segment focus
  • Exhibit 42: Pfizer - Key offerings
  • Exhibit 43: Pfizer - Key customers
  • Exhibit 44: Validation techniques employed for market sizing
  • Exhibit 45: List of abbreviations
Back to Top